Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 03 2022
15 03 2022
Historique:
received:
27
07
2021
revised:
29
09
2021
accepted:
11
11
2021
pubmed:
19
11
2021
medline:
16
4
2022
entrez:
18
11
2021
Statut:
ppublish
Résumé
Primary analysis of VISION showed tepotinib had durable clinical activity in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC). We present updated outcomes for clinically relevant subgroups. This phase II, open-label, multi-cohort study of 500 mg (450 mg active moiety) tepotinib in patients with METex14 skipping NSCLC assessed efficacy and safety in predefined subgroups according to age, prior therapies (chemotherapy and immune checkpoint inhibitors), and brain metastases. An ad hoc retrospective analysis using Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria assessed intracranial activity. 152 patients were evaluable for efficacy (median age: 73.1). Overall, objective response rate (ORR) was 44.7% [95% confidence interval (CI): 36.7-53.0]. Patients aged <75 (n = 84) and ≥75 (n = 68) had ORRs of 48.8% (95% CI: 37.7-60.0) and 39.7% (95% CI: 28.0-52.3), respectively. Treatment-naïve (n = 69) versus previously treated (n = 83) patients showed consistent efficacy [ORR (95% CI): 44.9% (32.9-57.4) vs. 44.6% (33.7-55.9); median duration of response (95% CI): 10.8 (6.9-not estimable) vs. 11.1 (9.5-18.5) months]. Of 15 patients analyzed by RANO-BM (12 received prior radiotherapy), 13 achieved intracranial disease control; 5 of 7 patients with measurable brain metastases had partial intracranial responses. Of 255 patients evaluable for safety, 64 (25.1%) experienced grade ≥3 treatment-related adverse events (TRAE), leading to discontinuation in 27 patients (10.6%). Rates of adverse events (AE) were broadly consistent irrespective of prior therapies. Tepotinib showed meaningful activity across subgroups by age, prior therapies, and brain metastases, with a manageable safety profile and few treatment discontinuations. See related commentary by Rosner and Spira, p. 1055.
Identifiants
pubmed: 34789481
pii: 1078-0432.CCR-21-2733
doi: 10.1158/1078-0432.CCR-21-2733
pmc: PMC9365370
doi:
Substances chimiques
Antineoplastic Agents
0
Piperidines
0
Pyridazines
0
Pyrimidines
0
tepotinib
1IJV77EI07
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1117-1126Subventions
Organisme : NCI NIH HHS
ID : K12 CA090625
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
©2021 The Authors; Published by the American Association for Cancer Research.
Références
Oncologist. 2020 Oct;25(10):822-825
pubmed: 33400286
N Engl J Med. 2020 Sep 3;383(10):931-943
pubmed: 32469185
CPT Pharmacometrics Syst Pharmacol. 2021 May;10(5):428-440
pubmed: 33818908
Cancer Commun (Lond). 2021 Jan;41(1):83-87
pubmed: 33387444
J Clin Oncol. 2016 Mar 1;34(7):721-30
pubmed: 26729443
J Med Econ. 2021 Jan-Dec;24(1):131-139
pubmed: 33397178
Cancer Discov. 2015 Aug;5(8):842-9
pubmed: 25971939
JCO Precis Oncol. 2020 Jul 27;4:
pubmed: 32923895
N Engl J Med. 2020 Sep 3;383(10):944-957
pubmed: 32877583
Ann Oncol. 2021 Nov;32(11):1332-1347
pubmed: 34364998
Ann Oncol. 2018 Oct 1;29(10):2085-2091
pubmed: 30165371
J Thorac Oncol. 2021 May;16(5):850-859
pubmed: 33545388
Drugs. 2020 Jun;80(8):829-833
pubmed: 32361823
Clin Cancer Res. 2016 Jun 15;22(12):3048-56
pubmed: 26847053
Cold Spring Harb Mol Case Stud. 2020 Dec 17;6(6):
pubmed: 33335011
J Clin Oncol. 2020 May 10;38(14):1608-1632
pubmed: 31990617
Lung Cancer. 2019 Jul;133:96-102
pubmed: 31200835
Cancers (Basel). 2019 Dec 17;11(12):
pubmed: 31861060
Curr Oncol. 2013 Aug;20(4):e300-6
pubmed: 23904768
Cancer Discov. 2015 Aug;5(8):850-9
pubmed: 25971938
Nat Med. 2020 Jan;26(1):47-51
pubmed: 31932802
Thorac Cancer. 2021 Mar;12(6):978-980
pubmed: 33533182
Clin Cancer Res. 2020 Mar 15;26(6):1237-1246
pubmed: 31822497
Lung Cancer. 2021 Sep;159:96-106
pubmed: 34320421